079 54654 056465

Aim and scope

Biomedical Engineering (BE) is an English medical journal which is published quarterly by Collaboration among Research Center of Smart Molecule of Natural Genetics Resources, Research Center of Osteoporosis, and Research Center of Advance System and Materials Technology in Indonesia and distributed worldwide. The articles published mainly deal with the research, industrial and commercial aspects of biotechnology, in areas such as: Biomedicine; Biomedical Engineering; Bioinformatics; Biocatalysis, Biosensor & Biosensing; Biotechnology; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Healthcare and Pharmaceuticals; Nutrigenomics and Nutrigenetics; Nanotechnology. Original scientific researches, timely reviews, case reports, short communications, and letters to the editor related to the research and practice of biomedical engineering are encouraged. BE provides a forum for communicating such interdisciplinary research, as well as relevant results in the constituent areas of biomedicine, biochemistry, molecular biology, applied microbiology, cellular physiology, cellular nutrition in health and disease, and biochemical engineering. At present, there is no page charge for this journal.

 

Terms of Submission

Papers must be submitted on the understanding that they have not been published previously and are not under consideration for publication elsewhere. The submitting author is responsible for ensuring that the article’s publication has been approved by all the other coauthors. It is also the authors’ responsibility to ensure that the articles emanating from a particular institution are submitted with the approval of the necessary institution. Only an acknowledgment from the editorial office officially establishes the date of receipt. Further correspondence and proofs will be sent to the author(s) before publication unless otherwise indicated. It is a condition of submission of a paper that the authors permit editing of the paper for readability.

 

During the online submission, authors will be prompted to submit a Novelty Statement to accompany their manuscript. The statement must provide information as to what is novel in the manuscript and what the advantages are compared with other articles reported so far. This statement will be taken into consideration by referees when reviewing the manuscript.

Peer Review

All manuscripts are subject to peer review and are expected to meet standards of academic excellence. Submissions will be considered by an editor and “if not rejected right away” by peer-reviewers, whose identities will remain anonymous to the authors.

 

Title and Authorship Information

The following information should be included

  • Paper title
  • Full author names
  • Full institutional mailing addresses
  • Email addresses

 

Abstract

The manuscript should contain an abstract. The abstract should be self-contained and citation-free and should not exceed 300 words. It contains objective, material & methods, result, conclusion.

 

Introduction

This section should be succinct with no subheadings, provide an adequate background, and state the objectives of the work undertaken.

 

Material and methods

This part should contain sufficient detail so that all procedures can be repeated. It can be divided into subsections if several methods are described.

 

Results

In this section author should describe the main findings in the text as well as the particular statistical significance of the data, and refer the reader to the tables and figures, implying that details are shown there. Information on significance and other statistical data should preferably be given in the tables and figures. Do not combine the Results and Discussion sections for full-length papers.

 

Discussion

This section should not repeat results. The discussion section should discuss study findings, and interpret them in the context of other trials reported in the literature providing evidence or counterevidence. In this way the validity of the results and the significance of the conclusions for the application in further research are assessed, with respect to the hypothesis, relevance of methods, and significance of differences observed.

 

Conclusions

This should clearly explain the main conclusions of the work highlighting its importance and relevance.

 

Acknowledgments

All acknowledgments (if any) should be included at the very end of the paper before the references and may include supporting grants, presentations, and so forth.

 

Reference

Authors are responsible for ensuring that the information in each reference is complete and accurate. All references must be numbered consecutively and citations of references in text should be identified using numbers in square brackets (e.g., “as discussed by Smith [9]”; “as discussed elsewhere [9, 10]”). All references should be cited within the text; otherwise, these references will be automatically removed.

 

Citing article in journal:

  1. Van der Slik AR, Koeleman BPC, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA matched control subjects. Diabetes. 2003:52:2639–42.
  2. Sharp AJ, Hansen S, Selzer RR, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet. 2006;38:1038-42.

 

Citing a book:

  1. McEvoy GK, ed. AHFS: Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1125-1126.

 

Chapter in book:

  1. Wallace RJ Jr, Griffith DE. Antimycobacterial agents. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison’s Principles of Internal Medicine. 16th ed. New York, NY: McGraw- Hill; 2005:946.

 

 

Online Journals (journal article) on Internet:

  1. Seal A, Kerac M. Operational implications of using 2006 World Health Organization growth standards in nutrition programmes: secondary data analysis. BMJ. 2007;334:733. http://www.bmj.com/cgi/content/full/334/7596/733. Accessed April 12, 2007.

 

General Internet:

FDA/CEDR resources page. Food and Drug Administration Web site. http://www.fda.gov/ cder/ approval/index.htm. Accessed April 7, 2007.

 

Preparation of Figure

Upon submission of an article, authors are supposed to include all figures and tables in the PDF file of the manuscript. Figures and tables should not be submitted in separate files. If the article is accepted, authors will be asked to provide the source files of the figures. Each figure should be supplied in a separate electronic file. All figures should be cited in the paper in a consecutive order. Figures should be supplied in either vector art formats (Illustrator, EPS, WMF, FreeHand, CorelDraw, PowerPoint, Excel, etc.) or bitmap formats (Photoshop, TIFF, GIF, JPEG, etc.). Bitmap images should be of 300 dpi resolution at least unless the resolution is intentionally set to a lower level for scientific reasons. If a bitmap image has labels, the image and labels should be embedded in separate layers.

 

Preparation of Table

Tables should be cited consecutively in the text. Every table must have a descriptive title and if numerical measurements are given, the units should be included in the column heading. Vertical rules should not be used.

 

Proofs

Corrected proofs must be returned to the publisher within 2-3 days of receipt. The publisher will do everything possible to ensure prompt publication. It will therefore be appreciated if the manuscripts and figures conform from the outset to the style of the journal.

 

Disclosure Policy

Open Access authors retain the copyrights of their papers, and all open access articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

 

Copyright

A competing interest exists when professional judgment concerning the validity of research is influenced by a secondary interest, such as financial gain. We require that our authors reveal any possible conflict of interests in their submitted manuscripts.If there is no conflict of interests, authors should state that “The author(s) declare(s) that there is no conflict of interests regarding the publication of this paper.”

 

Ethical guidelines

In any studies that involve experiments on human or animal subjects, the following ethical guidelines must be observed. For any human experiments, all work must be conducted in accordance with the Declaration of Helsinki (1964). Papers describing experimental work on human subjects who carry a risk of harm must include a statement that the experiment was conducted with the understanding and the consent of the human subject, as well as a statement that the responsible Ethical Committee has approved the experiments. In the case of any animal experiments, the authors should provide a full description of any anesthetic and surgical procedure used, as well as evidence that all possible steps were taken to avoid animal suffering at each stage of the ex

Logo IGN-TTRC

 

 

 

 

 

Indonesian- Geman Network for Teaching, Training and Research Collaborations (IGN-TTRC) merupakan program kolaborasi universitas- universitas di Indonesia dan jerman yang didukung oleh DAAD  ( Deutscher Academischer Austausch Dienst ). Program ini berbasis pada pelatihan dan kolaborasi penelitian selama 2 minggu untuk Training of Trainer (Dosen) dan seminggu untuk mahasiswa yang dilakukan di Universitas Brawijaya. Tema untuk tahun keempat modul V ini adalah tentang Biokimia yang melibatkan UB, UNAND, UNSRAT, UNEJ, IPB, UNMUL, dan UNAIR. Program ini akan diadakan pada tanggal 11- 22 Agustus 2014 untuk ToT (Dosen) dan tanggal 18- 22 Agustus 2014 untuk SC (mahasiswa) di Laboratorium Biosains Universitas Brawijaya, Malang. Pendaftaran terakhir dilakukan pada tanggal 30 Juni 2014 dengan format application form dapat dibuka di  http://fatchiyah.lecture.ub.ac.id/. atau dapat juga di download file berikut ini :

module-5-IGNTTRC-UB-Council-Application-Announce-biochemistry

IGN-TTRC-Application-form-module-V

IGN-TTRC-Application-form-module-V Word